The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis

被引:72
|
作者
vanMiert, MM
Eastwood, NB
Boyd, AH
Parker, CJR
Hunter, JM
机构
[1] University Department of Anaesthesia, Royal Liverpool University Hospital, Liverpool
[2] University Department of Anaesthesia, Royal Liverpool University Hospital, Liverpool L69 3BX, Prescot Street
关键词
hepatic cirrhosis; neuromuscular block; rocuronium;
D O I
10.1046/j.1365-2125.1997.00653.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To determine the effects of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of rocuronium bromide. Methods We studied 21 healthy patients and 17 patients with mild or moderate cirrhosis (Child-Pugh Class A and B). Patients were premedicated with diazepam orally; anaesthesia was induced with fentanyl and thiopentone, and maintained with isoflurane 0.6% (end-tidal) and nitrous oxide 66% in oxygen. The compound action potential of the adductor pollicis muscle in response to supramaximal stimulation of the ulnar nerve was recorded using the train-of-four (TOF) twitch technique. A bolus dose of rocuronium 0.6 mg kg(-1) was then given. Venous blood samples were taken for up to 8 h, and plasma rocuronium concentrations determined by h.p.l.c. Results The time to onset of neuromuscular block and maximal block achieved did not differ between the two groups. The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T-1:T-0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T-1:T-0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T-1:T-0, 84.2 (24.5) vs 66.8 (27.2) min (all P < 0.05); recovery of T-4:T-1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P < 0.01). A pharmacokinetic and pharmacodynamic model was fitted to the data for each patient. Three compartments were used to model the pharmacokinetic data; an effect compartment was added to model the pharmacodynamic data. Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min; P < 0.005). The central (V-1) and steady state volumes of distribution (V-ss) did not differ significantly between the groups. The slow redistribution (t(1/2 lambda 1)) and elimination (t(1/2,z)) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively). The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship C-P50(ss) and gamma. Conclusions Hepatic elimination is an important pathway in the clearance of rocuronium, and delayed disposition causes the effect to be prolonged.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 50 条
  • [1] PHARMACOKINETICS AND PHARMACODYNAMICS OF ROCURONIUM IN PATIENTS WITH CIRRHOSIS
    KHALIL, M
    DHONNEUR, G
    DUVALDESTIN, P
    SLAVOV, V
    DEHYS, C
    GOMENI, R
    [J]. ANESTHESIOLOGY, 1994, 80 (06) : 1241 - 1247
  • [2] PHARMACODYNAMICS OF ROCURONIUM IN PATIENTS WITH HEPATIC CIRRHOSIS
    BOYD, AH
    VANMIERT, MM
    EASTWOOD, NB
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1994, 73 (02) : P262 - P262
  • [3] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PERINDOPRIL IN PATIENTS WITH HEPATIC CIRRHOSIS
    TSAI, HH
    LEES, KR
    HOWDEN, CW
    REID, JL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (02) : P212 - P213
  • [4] Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
    Marino, MR
    Langenbacher, KM
    Raymond, RH
    Ford, NF
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (04): : 347 - 356
  • [5] Omapatrilat in patients with hepatic cirrhosis - Pharmacodynamics and pharmacokinetics
    O'Grady, P
    Vesterqvist, O
    Malhotra, B
    Manning, J
    Jemal, M
    Ge, G
    Mangold, B
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (03) : 249 - 257
  • [6] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PERINDOPRIL IN PATIENTS WITH HEPATIC CIRRHOSIS
    TSAI, HH
    LEES, KR
    HOWDEN, CW
    REID, JL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (01) : 53 - 59
  • [7] THE PHARMACOKINETICS OF ROCURONIUM BROMIDE IN HEPATIC CIRRHOSIS
    HUNTER, JM
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1995, 12 : 39 - 41
  • [8] ROCURONIUM PHARMACOKINETICS IN PATIENTS WITH CIRRHOSIS
    DHONNEUR, G
    KHALIL, M
    DUVALDESTIN, P
    [J]. ANESTHESIOLOGY, 1993, 79 (3A) : A357 - A357
  • [9] EFFECT OF HEPATIC CIRRHOSIS ON THE PHARMACOKINETICS OF ROCURONIUM BROMIDE
    VANMIERT, MM
    BOYD, AH
    EASTWOOD, NB
    PARKER, CJR
    HUNTER, JM
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1995, 75 (02) : P235 - P235
  • [10] PHARMACOKINETICS AND PHARMACODYNAMICS OF ROCURONIUM IN PATIENTS WITH CIRRHOSIS (REPRINTED FROM ANESTHESIOLOGY, VOL 80, 1994)
    KHALIL, M
    DHONNEUR, G
    DUVALDESTIN, P
    SLAVOV, V
    DEHYS, C
    GOMENI, R
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1994, : 85 - 86